'Strong guardrails key to GenAI success'

INDEGENE, a Bengaluru-based healthtech company is developing capabilities in generative AI to help pharma companies deliver drugs faster to patients, while bringing down the costs of sales & marketing for them.

- INTERVIEW: TARUN MATHUR, CTO, INDEGENE

INDEGENE, a Bengaluru-based healthtech company is developing capabilities in generative AI to help pharma companies deliver drugs faster to patients, while bringing down the costs of sales & marketing for them. The company offers a range of services including digital solutions, commercialisation strategies, and support for clinical trials, safety, and regulatory operations. In Q1FY26, Indegene maintained a trajectory of stable and profitable growth, recording ₹760.8 crore in revenues compared to ₹676.5 crore during Q1FY25. Tarun Mathur, CTO at Indegene speaks to Sudhir Chowdhary on how pharma companies can learn to scale GenAI and address the industry's unique challenges. Excerpts: